| Date Filed | Type | Description |
| 11/04/2020 |
GN
| CRISPR/Cas9 Gene-Editing Therapy CTX001™ for Severe Hemoglobinopathies Accepted for Plenary Presentation at the 62nd American Society of Hematology (ASH) Meeting and Exposition |
| 06/12/2020 |
GN
| CRISPR Therapeutics and Vertex Announce New Clinical Data for Investigational Gene-Editing Therapy CTX001™ in Severe Hemoglobinopathies at the 25th Annual European Hematology Association (EHA) Congress |
| 03/06/2019 |
GN
| Detailed Research: Economic Perspectives on KAR Auction Services, Spectrum Brands, Vertex Pharmaceuticals, The Kraft Heinz, comScore, and Retrophin — What Drives Growth in Today's Competitive Landscape |
| 02/25/2019 |
GN
| CRISPR Therapeutics and Vertex Announce Progress in Clinical Development Programs for the Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001 |
| 01/04/2019 |
GN
| CRISPR Therapeutics and Vertex Announce FDA Fast Track Designation for CTX001 for the Treatment of Sickle Cell Disease |
| 11/14/2018 |
GN
| Analysis: Positioning to Benefit within Vertex Pharmaceuticals, MISONIX, Whiting Petroleum, Kewaunee Scientific, Arotech, and Apollo Commercial Real Estate Finance — Research Highlights Growth, Revenue, and Consolidated Results |
| 10/10/2018 |
GN
| CRISPR Therapeutics and Vertex Announce FDA Has Lifted the Clinical Hold on the Investigational New Drug Application for CTX001 for the Treatment of Sickle Cell Disease |
| 08/10/2018 |
GN
| Factors of Influence in 2018, Key Indicators and Opportunity within Immunomedics, Vertex Pharmaceuticals, Ralph Lauren, Alliant Energy, TreeHouse Foods, and Lincoln National — New Research Emphasizes Economic Growth |
| 05/30/2018 |
GN
| CRISPR Therapeutics and Vertex Provide Update on FDA Review of Investigational New Drug Application for CTX001 for the Treatment of Sickle Cell Disease |
| 05/10/2018 |
GN
| Factors of Influence in 2018, Key Indicators and Opportunity within American Homes 4 Rent, Discovery Communications, Vertex Pharmaceuticals, The New York Times, Palatin Technologies, and E*TRADE Financial — New Research Emphasizes Economic Growth |
| 04/26/2018 |
BW
| Vertex Reports First-Quarter 2018 Financial Results |
| 04/17/2018 |
BW
| Vertex to Announce First Quarter 2018 Financial Results on April 26 |
| 03/09/2018 |
GN
| Consolidated Research: 2018 Summary Expectations for Envision Healthcare, Taylor Morrison Home, Vertex Pharmaceuticals, ReShape Lifesciences Inc., American Axle & Manufacturing, and Lattice Semiconductor — Fundamental Analysis, Key Performance Indications |
| 01/03/2018 |
BW
| Vertex Announces Upcoming Presentation at the J.P. Morgan Healthcare Conference and Date of Fourth-Quarter and Full-Year 2017 Financial Results |
| 11/15/2017 |
GN
| Investor Expectations to Drive Momentum within Barracuda Networks, Abraxas Petroleum, Vertex Pharmaceuticals, Incyte, Forum Energy, and S&P Global – Discovering Underlying Factors of Influence |
| 10/25/2017 |
BW
| Vertex Reports Third-Quarter 2017 Financial Results |
| 10/16/2017 |
BW
| Vertex to Announce Third Quarter 2017 Financial Results on October 25 |
| 07/26/2017 |
BW
| Vertex Reports Second-Quarter 2017 Financial Results |
| 07/25/2017 |
GN
| Vertex Energy, Inc. to Release Second Quarter 2017 Financial Results on August 8, 2017 |
| 07/13/2017 |
BW
| Vertex to Announce Second Quarter 2017 Financial Results on July 26 |
| 06/09/2017 |
BW
| Vertex to Present at the Goldman Sachs Healthcare Conference on June 13 |
| 04/27/2017 |
BW
| Vertex Reports First-Quarter 2017 Financial Results |
| 04/12/2017 |
BW
| Vertex to Announce First Quarter 2017 Financial Results on April 27 |
| 03/28/2017 |
BW
| Two Phase 3 Studies of the Tezacaftor/Ivacaftor Combination Treatment Met Primary Endpoints with Statistically Significant Improvements in Lung Function (FEV1) in People with Cystic Fibrosis |
| 07/05/2011 |
BW
| Vertex Announces the Date of its Second Quarter 2011 Financial Results Conference Call and Webcast |
| 05/26/2011 |
BW
| Vertex Announces Webcasts of its Presentations at Two Investor Conferences |
| 05/23/2011 |
BW
| FDA Approves INCIVEK™ (telaprevir) for People with Hepatitis C |
| 05/17/2011 |
BW
| Vertex Appoints Terrence C. Kearney to its Board of Directors |
| 05/03/2011 |
BW
| Vertex Reports First Quarter 2011 Financial Results and Reviews Milestones for Key Development Programs |
| 05/02/2011 |
BW
| Vertex Announces Webcasts of its Presentations at Two Investor Conferences |
| 04/28/2011 |
BW
| FDA Advisory Committee Unanimously Recommends Approval of Telaprevir for People with Hepatitis C |
| 04/15/2011 |
BW
| Vertex Announces the Date of its First Quarter 2011 Financial Results Conference Call and Webcast |
| 04/07/2011 |
BW
| Vertex and Cystic Fibrosis Foundation Therapeutics to Collaborate on Discovery and Development of New Medicines to Treat the Underlying Cause of Cystic Fibrosis |
| 03/31/2011 |
BW
| Data From Phase 3 Studies Showed Substantial Improvements in SVR (Viral Cure) Rates With Telaprevir-Based Therapy Compared to Currently Available Medicines in People With Hepatitis C, Regardless of Their IL28B Genotype Status |
|